Skip to main content Back to Top
Advertisement

11/8/2019

Etomidate Injection

Products Affected - Description

    • Amidate injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-6695-01
    • Amidate injection, Pfizer, 2 mg/mL, 20 mL LifeShield syringe, 10 count, NDC 00409-8060-29
    • Amidate injection, Pfizer, 2 mg/mL, 20 mL vial, 10 count, NDC 00409-6695-02
    • Etomidate injection, Athenex, 2 mg/mL, 10 mL vial, 10 count, NDC 70860-0652-10
    • Etomidate injection, Athenex, 2 mg/mL, 20 mL vial, 10 count, NDC 70860-0652-20
    • Etomidate injection, AuroMedics, 2 mg/mL, 10 mL vial, 10 count, NDC 55150-0221-10
    • Etomidate injection, AuroMedics, 2 mg/mL, 20 mL vial, 10 count, NDC 55150-0222-20
    • Etomidate injection, Zydus, 2 mg/mL, 10 mL vial, 10 count, NDC 68382-0545-07 - discontinued
    • Etomidate injection, Zydus, 2 mg/mL, 20 mL vial, 10 count, NDC 68382-0545-08 - discontinued

Reason for the Shortage

    • American Regent is not currently marketing etomidate.
    • Athenex did not provide a reason for the current shortage.
    • AuroMedics did not provide a reason for the current shortage.
    • Hikma has etomidate available.
    • Mylan Institutional has etomidate available.
    • Par Sterile Products discontinued etomidate in early 2015.
    • Pfizer has Amidate on shortage due to manufacturing delays. Pfizer discontinued etomidate ampules in October 2016.
    • Sagent is no longer marketing etomidate.
    • Zydus did not provide a reason for the shortage.

Available Products

    • Etomidate solution for injection, Fosun Pharma, 2 mg/mL, 10 mL vial, 10 count, NDC 72266-0146-10
    • Etomidate solution for injection, Fosun Pharma, 2 mg/mL, 20 mL vial, 10 count, NDC 72266-0147-10
    • Etomidate injection, Hikma, 2 mg/mL, 10 mL vial, 10 count, NDC 00143-9506-10
    • Etomidate injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9507-10
    • Etomidate injection, Mylan Institutional, 2 mg/mL, 10 mL vial, 10 count, NDC 67457-0902-10
    • Etomidate injection, Mylan Institutional, 2 mg/mL, 20 mL vial, 10 count, NDC 67457-0903-20

Estimated Resupply Dates

    • Athenex has etomidate 2 mg/mL 10 mL and 20 mL vials on back order and the company cannot estimate a release date.
    • AuroMedics has etomidate 2 mg/mL 10 mL and 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Pfizer has Amidate 2 mg/mL 10 mL vials on back order and the company estimates a release date of December 2019. The 20 mL vials are available in limited supply. The 2 mg/mL 20 mL LifeShield syringes on back order and the company estimates a release date of March 2020.

Safety

    • Clinicians must take extra care to ensure safe use of etomidate when using different presentations than those normally stocked.

Updated

Updated November 8, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 6, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins